Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL

Wang,Wenming; Wang,Jing; Li,Zhengqian; Zhu,Mingxia; Zhang,Zhe; Wang,Yanfang; Jing,Hongmei

doi:10.3892/or.2015.4347

Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL

Authors:
- Wenming Wang
- Jing Wang
- Zhengqian Li
- Mingxia Zhu
- Zhe Zhang
- Yanfang Wang
- Hongmei Jing
View Affiliations

Affiliations: Department of Hematology, Peking University Third Hospital, Beijing 100191, P.R. China, Department of Anesthesiology, Peking University Third Hospital, Beijing 100191, P.R. China, Department of Urology, Peking University Third Hospital, Beijing 100191, P.R. China
Published online on: October 26, 2015 https://doi.org/10.3892/or.2015.4347
Pages: 139-146

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant hypermethylation of CpG islands of tumor suppressor is one of the mechanisms for epigenetic loss of gene function. In the present study, the methylation status of the promoter regions of protein tyrosine phosphatase (PTPN) 6, DAPK, and p16 were studied using methylation-specific polymerase chain reaction (MSP) in 26 diffuse large B cell lymphoma (DLBCL) lymphomas. In OCI-LY1 cell line, gene methylation status, expression of PTPL1 and its reactivation by DNA demethylation was determined by PCR and on the protein level by western blotting. ELISA-like reaction was used to detect global DNA methylation measurement. Induction of apoptosis by 5-azacitidine was analyzed by Annexin V/PI staining and flow cytometry. Our results show that hypermethylation of the PTPN6 gene promoter region was found in 15.4% (4/26), the DAPK gene promoter region in 30.8% (8/26), the p16 gene promoter region in 7.7% (2/26). Notably, we identified that PTPL1 was hypermethylated and transcriptionally silenced in OCI-LY1 cell line. The expression of PTPL1 was re-inducible by 5-azacytidine. 5-azacytidine also inhibits the proliferation and decreases the global methylation level of the OCI-LY1 cell line. We can conclude from our study that a higher prevalence of methylation of PTPL1, PTPN6, DAPK and p16 occur in DLBCL. Our data also highlights 5-azacytidine as a potential therapeutic candidate for DLBCL. Further studies are required to substantiate the role of methylation of PTPL1, PTPN6, DAPK and p16 as a marker in diffuse large B cell lymphoma.

View Figures

View References

1	Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H and Jaffe ES: The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood. 117:5019–5032. 2011. View Article : Google Scholar : PubMed/NCBI
2	Young RM, Shaffer AL III, Phelan JD and Staudt LM: B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 52:77–85. 2015. View Article : Google Scholar : PubMed/NCBI
3	Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 109:1857–1861. 2007. View Article : Google Scholar
4	Jiang Y and Melnick A: The epigenetic basis of diffuse large B-cell lymphoma. Semin Hematol. 52:86–96. 2015. View Article : Google Scholar : PubMed/NCBI
5	Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, et al: Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 3:1002–1019. 2013. View Article : Google Scholar : PubMed/NCBI
6	Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O and Melnick A: DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 116:e81–e89. 2010. View Article : Google Scholar : PubMed/NCBI
7	Robaina MC, Mazzoccoli L, Arruda VO, Reis FR, Apa AG, de Rezende LM and Klumb CE: Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis. Exp Mol Pathol. 98:200–207. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zhao X, Yang F, Li S, Liu M, Ying S, Jia X and Wang X: CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression. Br J Haematol. 165:649–658. 2014. View Article : Google Scholar : PubMed/NCBI
9	Amara K, Ziadi S, Hachana M, Soltani N, Korbi S and Trimeche M: DNA methyltransferase DNMT3b protein over-expression as a prognostic factor in patients with diffuse large B-cell lymphomas. Cancer Sci. 101:1722–1730. 2010. View Article : Google Scholar : PubMed/NCBI
10	Freiss G and Chalbos D: PTPN13/PTPL1: An important regulator of tumor aggressiveness. Anticancer Agents Med Chem. 11:78–88. 2011. View Article : Google Scholar : PubMed/NCBI
11	Castilla C, Chinchón D, Medina R, Torrubia FJ, Japón MA and Sáez C: PTPL1 and PKCδ contribute to proapoptotic signalling in prostate cancer cells. Cell Death Dis. 4:e5762013. View Article : Google Scholar
12	Glondu-Lassis M, Dromard M, Chavey C, Puech C, Fajas L, Hendriks W and Freiss G: Downregulation of protein tyrosine phosphatase PTP-BL represses adipogenesis. Int J Biochem Cell Biol. 41:2173–2180. 2009. View Article : Google Scholar : PubMed/NCBI
13	Bodoor K, Haddad Y, Alkhateeb A, Al-Abbadi A, Dowairi M, Magableh A, Bsoul N and Ghabkari A: DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients. Asian Pac J Cancer Prev. 15:75–84. 2014. View Article : Google Scholar : PubMed/NCBI
14	Don KR, Ramani P, Ramshankar V, Sherlin HJ, Premkumar P and Natesan A: Promoter hypermethylation patterns of P16, DAPK and MGMT in oral squamous cell carcinoma: A systematic review and meta-analysis. Indian J Dent Res. 25:797–805. 2014. View Article : Google Scholar
15	Kupčinskaitė-Noreikienė R, Skiecevičienė J, Jonaitis L, Ugenskienė R, Kupčinskas J, Markelis R, Baltrėnas V, Sakavičius L, Semakina I, Grižas S, et al: CpG island meth-ylation of the MLH1, MGMT, DAPK, and CASP8 genes in cancerous and adjacent noncancerous stomach tissues. Medicina (Kaunas). 49:361–366. 2013.
16	Zhang Z, Nie F, Kang C, Chen B, Qin Z, Ma J, Ma Y and Zhao X: Increased periostin expression affects the proliferation, collagen synthesis, migration and invasion of keloid fibroblasts under hypoxic conditions. Int J Mol Med. 34:253–261. 2014.PubMed/NCBI
17	Liang Y, Li Z, Mo N, Li M, Zhuang Z, Wang J, Wang Y and Guo X: Isoflurane preconditioning ameliorates renal ischemia-reperfusion injury through antiinflammatory and antiapoptotic actions in rats. Biol Pharm Bull. 37:1599–1605. 2014. View Article : Google Scholar : PubMed/NCBI
18	Saleem M, Abbas K, Manan M, Ijaz H, Ahmed B, Ali M, Hanif M, Farooqi AA and Qadir MI: Review - epigenetic therapy for cancer. Pak J Pharm Sci. 28:1023–1032. 2015.PubMed/NCBI
19	Pike BL, Greiner TC, Wang X, Weisenburger DD, Hsu YH, Renaud G, Wolfsberg TG, Kim M, Weisenberger DJ, Siegmund KD, et al: DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia. 22:1035–1043. 2008. View Article : Google Scholar : PubMed/NCBI
20	Gibaja V, Shen F, Harari J, Korn J, Ruddy D, Saenz-Vash V, Zhai H, Rejtar T, Paris CG, Yu Z, et al: Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene. Apr 20–2015.(Epub ahead of print). http://dx.doi.org/10.1038/onc.2015.114. View Article : Google Scholar : PubMed/NCBI
21	Wang S and Wang Z: Epigenetic aberrant methylation of tumor suppressor genes in small cell lung cancer. J Thorac Dis. 5:532–537. 2013.PubMed/NCBI
22	Mehta A, Dobersch S, Romero-Olmedo AJ and Barreto G: Epige-netics in lung cancer diagnosis and therapy. Cancer Metastasis Rev. 34:229–241. 2015. View Article : Google Scholar : PubMed/NCBI
23	Witzig TE, Hu G, Offer SM, Wellik LE, Han JJ, Stenson MJ, Dogan A, Diasio RB and Gupta M: Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: Implications for epigenetic therapy. Leukemia. 28:147–154. 2014. View Article : Google Scholar :
24	Kristensen LS, Treppendahl MB, Asmar F, Girkov MS, Nielsen HM, Kjeldsen TE, Ralfkiaer E, Hansen LL and Grønbæk K: Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. Sci Rep. 3:27892013. View Article : Google Scholar : PubMed/NCBI
25	Koyama M, Oka T, Ouchida M, Nakatani Y, Nishiuchi R, Yoshino T, Hayashi K, Akagi T and Seino Y: Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest. 83:1849–1858. 2003. View Article : Google Scholar : PubMed/NCBI
26	Scarfò L and Ghia P: Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett. 155:36–39. 2013. View Article : Google Scholar : PubMed/NCBI
27	Gupta S and Knowlton AA: HSP60, Bax, apoptosis and the heart. J Cell Mol Med. 9:51–58. 2005. View Article : Google Scholar : PubMed/NCBI
28	Zeng J, Chen S, Li N, Chen L, Su J, Niu G, Zhu S and Liang Y: Sasanquasaponin from Camellia oleifera Abel. induces apoptosis via Bcl-2, Bax and caspase-3 activation in HepG2 cells. Mol Med Rep. 12:1997–2002. 2015.PubMed/NCBI
29	Chang C, Swaan PW, Ngo LY, Lum PY, Patil SD and Unadkat JD: Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. Mol Pharmacol. 65:558–570. 2004. View Article : Google Scholar : PubMed/NCBI
30	Pastor-Anglada M and Pérez-Torras S: Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front Pharmacol. 6:132015. View Article : Google Scholar : PubMed/NCBI